Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship...
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is 'expensive' on P/E.
Target Price
The average target price of NEO is 15 and suggests 31% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell